BIOMAT Database Logo BIOMAT Database Logo

[Antifibrotic therapy in other fibrotic interstitial lung diseases than idiopathic pulmonary fibrosis]. 2021

Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
sajisrit@rm.dk.

Numerous studies have shown that perioperative heparin bridging in patients treated with a vitamin K antagonist leads to an increased incidence of bleeding and so far, there is no evidence that it leads to a significant reduction in postoperative thromboembolism as summarised in this review. Prophylactic dosage of heparin is recommended after major surgery. Heparin bridging is not relevant in patients receiving a direct oral anticoagulant due to the rapid onset and offset of action of DOACs.

UI MeSH Term Description Entries
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D014812 Vitamin K A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial
D054990 Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change. Cryptogenic Fibrosing Alveolitis,Familial Idiopathic Pulmonary Fibrosis,Fibrocystic Pulmonary Dysplasia,Fibrosing Alveolitis, Cryptogenic,Idiopathic Fibrosing Alveolitis, Chronic Form,Idiopathic Pulmonary Fibrosis, Familial,Interstitial Pneumonitis, Usual,Pulmonary Fibrosis, Idiopathic,Usual Interstitial Pneumonia,Cryptogenic Fibrosing Alveolitides,Dysplasia, Fibrocystic Pulmonary,Fibrocystic Pulmonary Dysplasias,Fibrosing Alveolitides, Cryptogenic,Idiopathic Pulmonary Fibroses,Interstitial Pneumonia, Usual,Pneumonitides, Usual Interstitial,Pneumonitis, Usual Interstitial,Pulmonary Dysplasia, Fibrocystic,Pulmonary Fibroses, Idiopathic,Usual Interstitial Pneumonias,Usual Interstitial Pneumonitides,Usual Interstitial Pneumonitis

Related Publications

Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
September 2019, European respiratory review : an official journal of the European Respiratory Society,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.
January 2022, International journal of molecular sciences,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Exertional Desaturation Is More Severe in Idiopathic Pulmonary Fibrosis Than in Other Interstitial Lung Diseases.
January 2023, Physical therapy research,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS.
January 2017, The Ulster medical journal,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore.
July 2022, Journal of thoracic disease,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
April 2023, International journal of molecular sciences,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
May 2021, The Lancet. Respiratory medicine,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases.
September 2013, Current opinion in pulmonary medicine,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases.
January 1983, Respiration; international review of thoracic diseases,
Sajitha Sophia Sritharan, and Line Kølner-Augustson, and Sissel Kronborg-White, and Thomas Skovhus Prior, and Janne Møller, and Elisabeth Bendstrup
Monocyte chemoattractant protein-1 in idiopathic pulmonary fibrosis and other interstitial lung diseases.
May 1994, Human pathology,
Copied contents to your clipboard!